Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

1.

End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma.

Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, Toomey CE, Hochberg EP, Canellos GP, Abramson JS.

Ann Oncol. 2011 Apr;22(4):910-5. doi: 10.1093/annonc/mdq549. Epub 2010 Oct 15.

PMID:
20952598
[PubMed - indexed for MEDLINE]
Free Article
2.

Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.

Okosun J, Warbey V, Shaw K, Montoto S, Fields P, Marcus R, Virchis A, McNamara C, Bower M, Cwynarski K.

AIDS. 2012 Apr 24;26(7):861-5. doi: 10.1097/QAD.0b013e32835213b1.

PMID:
22333746
[PubMed - indexed for MEDLINE]
3.

Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR.

Ann Oncol. 2005 Jul;16(7):1160-8. Epub 2005 Jun 6.

PMID:
15939713
[PubMed - indexed for MEDLINE]
Free Article
4.

FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D'Amore F, Boesen AM, Berthelsen AK, Specht L.

Blood. 2006 Jan 1;107(1):52-9. Epub 2005 Sep 8.

PMID:
16150944
[PubMed - indexed for MEDLINE]
Free Article
5.

Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.

Tseng D, Rachakonda LP, Su Z, Advani R, Horning S, Hoppe RT, Quon A, Graves EE, Loo BW Jr, Tran PT.

Radiat Oncol. 2012 Jan 19;7:5. doi: 10.1186/1748-717X-7-5.

PMID:
22260710
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients.

Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, Vaggelli L, Zanoni L, Argnani L, Baccarani M, Fanti S.

Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):4-12. doi: 10.1007/s00259-011-1916-8. Epub 2011 Sep 6.

PMID:
21894546
[PubMed - indexed for MEDLINE]
7.

The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.

Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, Luminari S, Vitolo U, Sancetta R, Iannitto E, Trentin L, Stelitano C, Tavera S, Biggi A, Castagnoli A, Versari A, Gregianin M, Pelosi E, Torchio P, Levis A.

Haematologica. 2006 Apr;91(4):475-81.

PMID:
16585014
[PubMed - indexed for MEDLINE]
Free Article
9.

Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.

Avigdor A, Bulvik S, Levi I, Dann EJ, Shemtov N, Perez-Avraham G, Shimoni A, Nagler A, Ben-Bassat I, Polliack A.

Ann Oncol. 2010 Jan;21(1):126-32. doi: 10.1093/annonc/mdp271. Epub 2009 Jul 16.

PMID:
19608615
[PubMed - indexed for MEDLINE]
Free Article
10.

18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's Lymphoma-comparison with CT.

Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN.

Leuk Lymphoma. 2000 Nov;39(5-6):543-53.

PMID:
11342337
[PubMed - indexed for MEDLINE]
11.

Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D'Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A.

J Clin Oncol. 2007 Aug 20;25(24):3746-52. Epub 2007 Jul 23.

PMID:
17646666
[PubMed - indexed for MEDLINE]
Free Article
12.

Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET.

Fanti S, Castellucci P, Stefoni V, Nanni C, Tani M, Rubello D, Ambrosini V, Zinzani PL, Franchi R.

Ann Nucl Med. 2008 Jun;22(5):429-32. doi: 10.1007/s12149-008-0105-8. Epub 2008 Jul 4.

PMID:
18600422
[PubMed - indexed for MEDLINE]
13.

The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.

Yang DH, Min JJ, Jeong YY, Ahn JS, Kim YK, Cho SH, Chung IJ, Bom HS, Kim HJ, Lee JJ.

Ann Hematol. 2009 May;88(5):425-32. doi: 10.1007/s00277-008-0616-3. Epub 2008 Nov 12.

PMID:
19002686
[PubMed - indexed for MEDLINE]
14.

18FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results.

Rigacci L, Castagnoli A, Dini C, Carpaneto A, Matteini M, Alterini R, Carrai V, Nassi L, Bernardi F, Pieroni C, Bosi A.

Oncol Rep. 2005 Nov;14(5):1209-14.

PMID:
16211287
[PubMed - indexed for MEDLINE]
15.

Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.

Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B, Khouri I, Younes A, Hagemeister F, Kwak L, Fayad L.

Cancer. 2007 Jun 15;109(12):2481-9.

PMID:
17497648
[PubMed - indexed for MEDLINE]
Free Article
16.

Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure.

Liao Z, Ha CS, Vlachaki MT, Hagemeister F, Cabanillas F, Hess M, Tucker S, Cox JD.

Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):971-7.

PMID:
11429225
[PubMed - indexed for MEDLINE]
17.

Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma.

Cremerius U, Fabry U, Neuerburg J, Zimny M, Bares R, Osieka R, Büll U.

Nuklearmedizin. 2001 Feb;40(1):23-30.

PMID:
11373935
[PubMed - indexed for MEDLINE]
18.

FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.

Querellou S, Valette F, Bodet-Milin C, Oudoux A, Carlier T, Harousseau JL, Chatal JF, Couturier O.

Ann Hematol. 2006 Nov;85(11):759-67. Epub 2006 Jul 27.

PMID:
16871391
[PubMed - indexed for MEDLINE]
19.

Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease.

Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ.

J Clin Oncol. 2007 Sep 1;25(25):3902-7. Epub 2007 Jul 30.

PMID:
17664458
[PubMed - indexed for MEDLINE]
Free Article
20.

18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.

Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M, Trindade E, Soares J Jr, Buccheri V, Meneghetti JC.

J Nucl Med. 2010 Sep;51(9):1337-43. doi: 10.2967/jnumed.109.073197. Epub 2010 Aug 18. Erratum in: J Nucl Med. 2010 Oct;51(10):1658.

PMID:
20720036
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk